Yesterday, Kyle Bass and his hedge funds opened a new front in their war against patent owners (on which we have reported previously) by filing three new IPR petitions. This time, the Bass Coalition has attacked U.S. Patent Nos. 7,582,621 (IPR2015-01776) and 7,767,657 (IPR2015-01780 and IPR2015-01785). Assigned to Anacor Pharmaceuticals, Inc., these patents cover KERYDIN® (tavaborole), which is an antifungal medication approved by the FDA for treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.
On the same day in related IPR proceedings, Celgene responded to the Coalition’s defense of this unusual market manipulation strategy (see, for example, IPR2015-01103 Paper 19).